| Plasma CCL5 promotes EMT-medicated epirubicin-resistance in locally advanced breast cancer | |
| Ma, Ge; Huang, Huaxing; Li, Minghui; Li, Li; Kong, Peng; Zhu, Yichao; Xia, Tiansong; Wang, Shui | |
| 刊名 | CANCER BIOMARKERS
 |
| 2018 | |
| 卷号 | 22期号:3 |
| 关键词 | Neoadjuvant chemotherapy breast cancer CCL5 predictive marker |
| ISSN号 | 1574-0153 |
| URL标识 | 查看原文 |
| 语种 | 英语 |
| 内容类型 | 期刊论文 |
| URI标识 | http://www.corc.org.cn/handle/1471x/3599610 |
| 专题 | 复旦大学上海医学院 |
| 推荐引用方式 GB/T 7714 | Ma, Ge,Huang, Huaxing,Li, Minghui,et al. Plasma CCL5 promotes EMT-medicated epirubicin-resistance in locally advanced breast cancer[J]. CANCER BIOMARKERS,2018,22(3). |
| APA | Ma, Ge.,Huang, Huaxing.,Li, Minghui.,Li, Li.,Kong, Peng.,...&Wang, Shui.(2018).Plasma CCL5 promotes EMT-medicated epirubicin-resistance in locally advanced breast cancer.CANCER BIOMARKERS,22(3). |
| MLA | Ma, Ge,et al."Plasma CCL5 promotes EMT-medicated epirubicin-resistance in locally advanced breast cancer".CANCER BIOMARKERS 22.3(2018). |
| 个性服务 |
| 查看访问统计 |
| 相关权益政策 |
| 暂无数据 |
| 收藏/分享 |
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。
修改评论